Skip to main content
Equibles
NBIX logo

NBIX · Neurocrine Biosciences Inc

Track NBIX — free

Use NBIX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$155.64 -2.71 (-1.71%) At close · Sep 4
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$16.10B
Shares
101.65M

NBIX metrics

75 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$155.64
Market cap
$16.10B

Price action

19 metrics
Price change (1W)
+1.6%
Price change (30D)
-0.9%
Price change (3M)
-5.4%
Price change (6M)
+22.1%
Price change (YTD)
+11.6%
Price change (1Y)
+16.3%
Trailing year
Price change (5Y)
+65.2%
52-week high
$185.50
52-week low
$123.10
Change from 52-week high
-14.6%
Change from 52-week low
+28.6%
Annualized volatility
33.2%
Beta
0.7
RSI (14D)
48.6
Price vs SMA 50
-4.6%
Price vs SMA 200
+7.4%
Avg volume (3M)
1.23M
Relative volume
0.6
Average dollar volume
$203.50M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
101.65M

Valuation

12 metrics
P / E (TTM)
23.2
Trailing earnings · reciprocal yield 4.3%
PEG ratio
0.7
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.8×
reciprocal yield 21.0%
P / book
4.4
reciprocal yield 22.9%
FCF yield
—
TTM · current market cap
Buyback yield
0.4%
P / FCF
—
P / operating cash flow
17.9
reciprocal yield 5.6%
Earnings yield
4.4%

Historical valuation

8 metrics
P / E historical average (3Y)
39.4×
reciprocal yield 2.5%
P / E historical average (5Y)
95.4×
reciprocal yield 1.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
98.2%
Operating margin
23.6%
Trailing 12 months
Net margin
20.9%
Gross profit (TTM)
—
Operating profit (TTM)
$794.80M
Net income (TTM)
$705.50M
Trailing 12 months
Diluted EPS (TTM)
$6.83
FCF margin
—
Effective tax rate
25.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
$0.49
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.35

Growth

11 metrics
Revenue growth YoY
+39.5%
Year over year
Net income growth YoY
+34.3%
Revenue (TTM)
$3.37B
Trailing 12 months
EPS growth YoY
+31.1%
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
+24.3%
Revenue CAGR (5Y)
+22.3%
EPS CAGR (3Y)
+44.1%
EPS CAGR (5Y)
+2.3%
FCF CAGR (3Y)
+32.4%
FCF CAGR (5Y)
+28.0%

Quality

14 metrics
Return on equity
19.1%
Return on assets
13.2%
Debt / equity
—
Current ratio
1.9
EBITDA (TTM)
$51.91M
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$332.40M
Total assets
$5.36B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$898.10M
Capital expenditures (TTM)
—
R&D (TTM)
$1.13B
SG&A (TTM)
$1.35B
Stock compensation (TTM)
$234.50M
R&D / revenue
33.5%
Stock compensation / revenue
7.0%

Ownership (13F)

3 metrics
13F filers
775
13F filer change QoQ
+74
Institutional ownership
100.0%

Short interest

3 metrics
Short interest
4.5%
Latest settlement · 3.4 days to cover
Days to cover
3.4d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.12M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 914475 CUSIP 64125C109 13F (30d) 467 filings 455 filers Visit website Investor relations